GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qurient Co Ltd (XKRX:115180) » Definitions » Return-on-Tangible-Equity

Qurient Co (XKRX:115180) Return-on-Tangible-Equity : -45.39% (As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is Qurient Co Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Qurient Co's annualized net income for the quarter that ended in Mar. 2025 was ₩-23,791 Mil. Qurient Co's average shareholder tangible equity for the quarter that ended in Mar. 2025 was ₩52,418 Mil. Therefore, Qurient Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2025 was -45.39%.

The historical rank and industry rank for Qurient Co's Return-on-Tangible-Equity or its related term are showing as below:

XKRX:115180' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -81.38   Med: -61.57   Max: -43.57
Current: -51.1

During the past 11 years, Qurient Co's highest Return-on-Tangible-Equity was -43.57%. The lowest was -81.38%. And the median was -61.57%.

XKRX:115180's Return-on-Tangible-Equity is ranked worse than
54.45% of 1258 companies
in the Biotechnology industry
Industry Median: -43.075 vs XKRX:115180: -51.10

Qurient Co Return-on-Tangible-Equity Historical Data

The historical data trend for Qurient Co's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qurient Co Return-on-Tangible-Equity Chart

Qurient Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -56.40 -43.57 -65.90 -58.47 -47.48

Qurient Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -49.91 -68.33 -45.79 -44.41 -45.39

Competitive Comparison of Qurient Co's Return-on-Tangible-Equity

For the Biotechnology subindustry, Qurient Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qurient Co's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Qurient Co's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Qurient Co's Return-on-Tangible-Equity falls into.


;
;

Qurient Co Return-on-Tangible-Equity Calculation

Qurient Co's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-23567.158/( (44035.156+55233.934 )/ 2 )
=-23567.158/49634.545
=-47.48 %

Qurient Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=-23790.86/( (55233.934+49602.991)/ 2 )
=-23790.86/52418.4625
=-45.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2025) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Qurient Co  (XKRX:115180) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Qurient Co Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Qurient Co's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Qurient Co Business Description

Traded in Other Exchanges
N/A
Address
C-dong 8th Floor, 242, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, KOR, 13487
Qurient Co Ltd is a South Korea based biotech company. It is engaged in network research & development business model, integrating research and drug development programs with a new mechanism. Its pipeline products include Q301 for the treatment of atopic dermatitis; Q203 treats MDR/XDR/TDR TB, and Q701 is a drug-resistant cancer immuno-oncology.

Qurient Co Headlines

No Headlines